Wedge Capital Management L L P NC Increases Stock Holdings in Solventum Co. (NYSE:SOLV)

Wedge Capital Management L L P NC boosted its stake in shares of Solventum Co. (NYSE:SOLV) by 7.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 75,283 shares of the company’s stock after acquiring an additional 5,094 shares during the period. Wedge Capital Management L L P NC’s holdings in Solventum were worth $4,973,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SOLV. Copeland Capital Management LLC acquired a new position in shares of Solventum during the 3rd quarter worth about $26,000. Modus Advisors LLC purchased a new stake in Solventum during the 4th quarter worth approximately $25,000. Mather Group LLC. purchased a new stake in Solventum during the 3rd quarter worth approximately $27,000. Hollencrest Capital Management purchased a new position in shares of Solventum in the second quarter valued at approximately $25,000. Finally, True Wealth Design LLC lifted its position in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after acquiring an additional 471 shares in the last quarter.

Solventum Stock Performance

SOLV stock opened at $73.60 on Friday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The firm’s 50 day moving average price is $69.12 and its 200-day moving average price is $65.49. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SOLV. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. Wolfe Research started coverage on shares of Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus began coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.